SugarStrings.ai uses simple cheek swabs to identify thousands of genetic disorders

Tony Jose, a former genomics researcher and CEO of Clevergene Biocorp, founded SugarStrings in 2023 with the goal of making genetic disorder testing more accessible and comprehensive. The startup's flagship product, Healthstring, is a DNA sequencing test that screens for over 7,442 genetic disorders using a single cheek swab sample.

This non-invasive approach is easier for sample collection and avoids challenges like cold chains, while also providing people with a sense of proactive health management. The cost of the test is currently Rs 58,000, with reports delivered between five days and one month.

Jose emphasizes that SugarStrings goes beyond simply identifying an individual's likelihood of developing a condition. The company provides a detailed report on all possible diseases that can come from a specific DNA mutation, enabling clinical action to be taken. Healthstring screens for 7,442 disorders, including 188 hereditary cancers and 302 cardiovascular diseases, which surpasses competitors such as Nucleus Genomics and Strand Life Sciences.

The company's focus on a comprehensive test rather than condition-specific screening is based on the understanding that the human body is a connected system, where diseases affecting one organ can have far-reaching effects on overall function. As DNA sequencing becomes cheaper and larger volumes and technology implementations come into play, SugarStrings aims to make its test more affordable.

Additionally, the startup is working on improving genetic analysis across diverse populations by identifying novel mutations with 94.89% accuracy using a proprietary machine learning-based crawler. This allows the company to analyze genetic data across more diverse populations.